Home › All Companies › TYRA

Tyra Biosciences, Inc. (TYRA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-02-13

Key Insights

  • The reporting person, Daniel Bensen, who is the Chief Discovery Officer, sold 8,000 shares of the company's common stock on February 12, 2026 pursuant to a Rule 10b5-1 trading plan.
  • The total number of shares beneficially owned by the reporting person following the reported transactions is 146,981 shares.
  • The reporting person sold the shares at an average price of $31.50 and $33.37 per share, indicating potential insider selling activity.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-20

Key Insights

  • The reporting person, Daniel Bensen, who is the Chief Discovery Officer of Tyra Biosciences, Inc. (TYRA), sold 8,000 shares of the company's common stock on 01/12/2026 under a pre-established Rule 10b5-1 trading plan.
  • The sale was executed at a weighted average price of $28.44 and $29.08 per share, resulting in a total sale of approximately $232,000.
  • Following the reported transaction, the reporting person still holds 154,981 shares of the company's common stock, indicating continued ownership and commitment to the company.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.